PuSH - Publication Server of Helmholtz Zentrum München: Dendritic cells for the induction of EBV immunity.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Subklewe, M.*

Dendritic cells for the induction of EBV immunity.

Recent Results Cancer Res. 159, 38-43 (2002)

PMC

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

Cell-mediated immunity provides resistance to Epstein-Barr virus (EBV), as demonstrated by the occurrence of EBV-induced post-transplant lymphoproliferative disease (PTLPD) in immunosuppressed patients. T cell immunity is stimulated most effectively by dendritic cells (DCs). Although DCs are not direct targets for infection by EBV, we tested whether EBV antigens are cross-presented by human DCs and whether DCs are efficient at stimulation of EBV-specific CD8+ T cells. We show that DCs cross-presenting apoptotic or necrotic lymphoblastoid cell lines (LCLs) are able to expand CD8+ T cells that directly recognize HLA-matched LCLs by IFN-gamma secretion and cytolytic activity. Part of this EBV-specific CD8+ T cell response was specific for the EBV nuclear antigen EBNA3 A and the latent membrane protein LMP2a. Both these antigens are expressed in PTLPD. In other EBV-associated malignancies such as Hodgkin' s lymphoma, T cell lymphoma and nasopharyngeal carcinoma, LMP2a is maintained. Therefore, the cross-presenting ability of DCs might be explored in DC-mediated active immunization against EBV-associated malignancies.

Impact Factor

Scopus SNIP

Altmetric

0.000